High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance-Reference-Cited by-同舟云学术

High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance

Published:2016-07-14 Issue:6 Volume:127 Page:516-523
ISSN:0020-7454
Container-title:International Journal of Neuroscience
language:en
Short-container-title:International Journal of Neuroscience

Author:

Hachulla E.,Benveniste O.,Hamidou M.,Mouthon L.,Schleinitz N.,Lozeron P.,Léger J.M.,Vial C.,Viala K.

Publisher

Informa UK Limited

Subject

General Medicine,General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/00207454.2016.1204544

Reference54 articles.

1. Dysphagia in Inflammatory Myopathy: Clinical Characteristics, Treatment Strategies, and Outcome in 62 Patients

2. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies

3. Treatment of dermatomyositis and polymyositis

4. Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects

5. Therapy of polymyositis and dermatomyositis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis;Journal of Comparative Effectiveness Research;2024-09

2. Adverse Reactions Associated with Intravenous Immunoglobulin Administration in the Treatment of Neurological Disorders: A Systematic Review;International Archives of Allergy and Immunology;2023

3. Update on Paraneoplastic Neuromuscular Disorders;Current Treatment Options in Neurology;2022-06-17

4. Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis;Autoimmunity Reviews;2022-02

5. Update on Myositis Therapy: from Today’s Standards to Tomorrow’s Possibilities;Current Pharmaceutical Design;2021-11-15